Transcript of last two minutes of video - a lot to be happy...

Transcript of last two minutes of video - a lot to be happy about in this!


"Pete, what are some of the upcoming key milestones this year that investors can look forward to?"

"Yeah, so there's going to continue to be a lot going on.

• Obviously we've got the cardio protection study that is on and we will be expanding the number of sites so we should see an acceleration in recruitment there.
• We're planning an investor day so we're going to be going through a lot a lot of these things in more detail and talking about more recent data.
• We'll expect the first patient to be treated relatively soon in the non-small cell lung cancer trial. That's definitely up and running.
• We're also looking to file a US investigational new drug application or an IND. Uh so that's going to be very important as well.
• And then there'll be updates on our patent strategy. We mentioned in the quarterly that we've received a preliminary examination on the competition matter claims. Um no surprise at all some of them got rejected, some of them seem to be fine. But importantly, there was no prior art cited against us. And that's normally, you know, something that can really burst your balloon if uh you get that waved at you. But the claims that were rejected, we feel very very comfortable that we can counter the arguments that's being made by the examiner. So that's going to be very important.
• And then later on, we'll be talking more about the AML clinical study.
• And then I mentioned the piggyback options we've got out there. We finished the quarter with over 20 million in the bank. So you know we should be well we'll be spending some along the way obviously but it's as if we've got 40 million in the bank at the moment.

So yeah, lots to look forward to. It's going to be a very very exciting year!"

(dot point format added by me for readability and to highlight just how much is coming)